All In Biotech

NDA 020987 · Wyeth Pharms

Protonix

Pantoprazole Sodium · Oral

NovelDiscontinued

Last checked: Nov 19, 2026Latest source record: Jul 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

Feb 2, 2000

Approved uses

4

Original approval plus efficacy supplements

Registered trials

231

49 Phase 3, 17 recruiting

FAERS reports

150,008

116,369 serious, 16,699 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 18, 2026.

PROTONIX For Delayed-Release Oral Suspension and PROTONIX Delayed-Release Tablets are indicated for: PROTONIX is a proton pump inhibitor (PPI) indicated for the following: • Short-Term Treatment of Erosive Esophagitis Associated with Gastroesophageal Reflux Disease (GERD) ( 1.1 ) • Maintenance of Healing of Erosive Esophagitis ( 1.2 ) • Pathological Hypersecretory Conditions Including Zollinger-Ellison (ZE) Syndrome ( 1.3 ) 1.1 Short-Term Treatment of Erosive Esophagitis Associated With Gastroesophageal Reflux Disease (GERD) PROTONIX is indicated in adults and pediatric patients five years of age and older for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis (EE). For those adult patients who have not healed after 8 weeks of treatment, an additional 8-week course of PROTONIX may be considered. Safety of treatment beyond 8 weeks in pediatric patients has not been established. 1.2 Maintenance of Healing of Erosive Esophagitis PROTONIX is indicated for maintenance of healing of EE and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with GERD. Controlled studies did not extend beyond 12 months. 1.3 Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome PROTONIX is indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison (ZE) Syndrome.

Mechanism: Pantoprazole is a PPI that suppresses the final step in gastric acid production by covalently binding to the (H + , K + )-ATPase enzyme system at the secretory surface of the gastric parietal cell. This effect leads to inhibition of both basal and stimulated gastric acid secretion, irrespective of the stimulus. The binding to the (H + , K + )-ATPase results in a duration of antisecretory effect that persists longer than 24 hours for all doses tested (20 mg to 120 mg).

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • PROTONIX · PANTOPRAZOLE SODIUM EQ 20MG BASE · TABLET, DELAYED RELEASE, ORAL · Discontinued · TE AB
  • PROTONIX · PANTOPRAZOLE SODIUM EQ 40MG BASE · TABLET, DELAYED RELEASE, ORAL · Discontinued · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Pantoprazole" as an intervention, any sponsor and status, largest first.

All 231 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • chronic kidney disease24,473
  • acute kidney injury13,898
  • fatigue11,669
  • renal failure10,884
  • nausea10,751
  • pain10,043
  • dyspnoea9,794
  • diarrhoea9,645
  • drug ineffective9,026
  • headache8,494
  • off label use8,235
  • end stage renal disease7,567

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,677
20052,530
20062,944
20072,609
20082,827
20093,147
20103,759
20113,562
20124,313
20133,291
20143,732
20155,932
20165,965
20175,590
201818,754
201916,519
20207,908
20218,696
202210,518
20238,441
20249,866
202510,012
20267,414

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Protonix (Pantoprazole Sodium)

2024 spending

$10.7M

Beneficiaries

3,219

11,573 claims

Per beneficiary

$3,309

$13.75 per unit

View as table
YearSpending
2020$39,919,620
2021$26,927,120
2022$16,715,512
2023$15,379,423
2024$10,650,066

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 616 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.